-- Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) logged a 14% rise in its attributable profit for the first quarter of 2026 to 870.8 million yuan from 764.8 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.
The pharmaceutical company's Hong Kong shares fell nearly 2% in late morning trade Wednesday.
Earnings per share were 0.33 yuan, compared with 0.29 yuan in the prior year.
Operating revenue gained nearly 7% to 10.1 billion yuan, figures showed.